Literature DB >> 22104138

The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion.

Ricardo Cáceda1, Elisabeth B Binder, Becky Kinkead, Charles B Nemeroff.   

Abstract

The neuropeptide neurotensin (NT) is closely associated with dopaminergic and glutamatergic systems in the rat brain. Central injection of NT into the nucleus accumbens (NAcc) or peripheral administration of NT receptor agonists, reduces many of the behavioral effects of psychostimulants. However, the role of endogenous NT in the behavioral effects of psychostimulants (e.g. DA agonists and NMDA receptor antagonists) remains unclear. Using a NTR antagonist, SR142948A, the current studies were designed to examine the role of endogenous NT in DA receptor agonist- and NMDA receptor antagonist-induced disruption of prepulse inhibition of the acoustic startle response (PPI), locomotor hyperactivity and brain-region specific c-fos mRNA expression. Adult male rats received a single i.p. injection of SR142948A or vehicle followed by D-amphetamine, apomorphine or dizocilpine challenge. SR142948A had no effect on baseline PPI, but dose-dependently attenuated d-amphetamine- and dizocilpine-induced PPI disruption and enhanced apomorphine-induced PPI disruption. SR142948A did not significantly affect either baseline locomotor activity or stimulant-induced hyperlocomotion. Systemic SR142948A administration prevented c-fos mRNA induction in mesolimbic terminal fields (prefrontal cortex, lateral septum, NAcc, ventral subiculum) induced by all three psychostimulants implicating the VTA as the site for NT modulation of stimulant-induced PPI disruption. Further characterization of the NT system may be valuable to find clinical useful compounds for schizophrenia and drug addiction. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104138      PMCID: PMC3595536          DOI: 10.1016/j.schres.2011.10.013

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  86 in total

1.  Amphetamine-elicited striatal Fos expression is attenuated in neurotensin null mutant mice.

Authors:  Jim Fadel; Paul R Dobner; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2006-04-24       Impact factor: 3.046

2.  The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition.

Authors:  P D Shilling; E Richelson; D Feifel
Journal:  Behav Brain Res       Date:  2003-07-14       Impact factor: 3.332

Review 3.  Neurotensin: role in psychiatric and neurological diseases.

Authors:  Ricardo Cáceda; Becky Kinkead; Charles B Nemeroff
Journal:  Peptides       Date:  2006-08-04       Impact factor: 3.750

Review 4.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  A neurotensin agonist and antagonist decrease and increase activity, respectively, but do not preclude discrete cue conditioning.

Authors:  C Norman; S K Grimond-Billa; G W Bennett; H J Cassaday
Journal:  J Psychopharmacol       Date:  2008-10-06       Impact factor: 4.153

6.  Central neurotensin receptor activation produces differential behavioral responses in Fischer and Lewis rats.

Authors:  Pat Bauco; Pierre-Paul Rompré
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

7.  Neurotensin afferents of the ventral tegmental area in the rat: [1] re-examination of their origins and [2] responses to acute psychostimulant and antipsychotic drug administration.

Authors:  Stefanie Geisler; Daniel S Zahm
Journal:  Eur J Neurosci       Date:  2006-07       Impact factor: 3.386

8.  Enhanced inhibition of synaptic transmission by dopamine in the nucleus accumbens during behavioral sensitization to cocaine.

Authors:  Corinne Beurrier; Robert C Malenka
Journal:  J Neurosci       Date:  2002-07-15       Impact factor: 6.167

9.  Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex.

Authors:  Réka Szakács; Roland Weiczner; András Mihály; Beáta Krisztin-Péva; Zsolt Zádor; Erno Zádor
Journal:  Brain Res Bull       Date:  2003-02-15       Impact factor: 4.077

10.  Dopamine D1 receptors and adenosine A1 receptors in the rat nucleus accumbens regulate motor activity but not prepulse inhibition.

Authors:  Isabel Schwienbacher; Markus Fendt; Wolfgang Hauber; Michael Koch
Journal:  Eur J Pharmacol       Date:  2002-05-31       Impact factor: 4.432

View more
  5 in total

1.  Striatal dopamine receptor plasticity in neurotensin deficient mice.

Authors:  Lucy G Chastain; Hongyan Qu; Chase H Bourke; P Michael Iuvone; Paul R Dobner; Charles B Nemeroff; Becky Kinkead
Journal:  Behav Brain Res       Date:  2014-11-15       Impact factor: 3.332

Review 2.  Synaptic Cytoskeletal Plasticity in the Prefrontal Cortex Following Psychostimulant Exposure.

Authors:  Lauren M DePoy; Shannon L Gourley
Journal:  Traffic       Date:  2015-06-01       Impact factor: 6.215

3.  ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse.

Authors:  Larry S Barak; Yushi Bai; Sean Peterson; Tama Evron; Nikhil M Urs; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick R Maloney; Thomas D Y Chung; Ramona M Rodriguiz; William C Wetsel; James B Thomas; Glen R Hanson; Anthony B Pinkerton; Marc G Caron
Journal:  ACS Chem Biol       Date:  2016-05-05       Impact factor: 5.100

4.  Antagonism of Neurotensin Receptors in the Ventral Tegmental Area Decreases Methamphetamine Self-Administration and Methamphetamine Seeking in Mice.

Authors:  Sergio Dominguez-Lopez; Elisabeth Piccart; William B Lynch; Mackenna B Wollet; Amanda L Sharpe; Michael J Beckstead
Journal:  Int J Neuropsychopharmacol       Date:  2018-04-01       Impact factor: 5.176

5.  Determination of neurotensin projections to the ventral tegmental area in mice.

Authors:  Hillary L Woodworth; Juliette A Brown; Hannah M Batchelor; Raluca Bugescu; Gina M Leinninger
Journal:  Neuropeptides       Date:  2018-02-15       Impact factor: 3.286

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.